Visceral adiposity index is associated with significant fibrosis in patients with non-alcoholic fatty liver disease

Alimentary Pharmacology and Therapeutics

Volumn 35, Issue 2, 2012, Pages 238-247

  Petta, S ^a   Amato, M C ^a   Di Marco, V ^a   Camma C ^a   Pizzolanti, G ^a   Barcellona, M R ^a   Cabibi, D ^a   Galluzzo, A ^a   Sinagra, D ^a   Giordano, C ^a   Craxi A ^a  

^a UNIVERSITY OF PALERMO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; HIGH DENSITY LIPOPROTEIN; INSULIN; INTERLEUKIN 6; LEPTIN; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA;

ADIPOSE TISSUE; ADULT; ANALYTICAL PARAMETERS; ARTICLE; BODY MASS; CLINICAL EXAMINATION; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INFLAMMATION; INSULIN RESISTANCE; LIPOPROTEIN BLOOD LEVEL; LIVER BIOPSY; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; METABOLIC PARAMETERS; NONALCOHOLIC FATTY LIVER; NONALCOHOLIC FATTY LIVER DISEASE ACTIVITY SCORE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SCORING SYSTEM; TRIACYLGLYCEROL BLOOD LEVEL; VISCERAL ADIPOSITY INDEX; WAIST CIRCUMFERENCE;

ADIPOSITY; ADULT; BIOPSY; BODY MASS INDEX; FATTY LIVER; FEMALE; HUMANS; INTRA-ABDOMINAL FAT; LIVER CIRRHOSIS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; REGRESSION ANALYSIS; RISK FACTORS; SEVERITY OF ILLNESS INDEX; WAIST CIRCUMFERENCE;

EID: 83855161551     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2011.04929.x     Document Type: Article

References (37)

1. Petta S, Muratore C, Craxì A,. Non-alcoholic fatty liver disease pathogenesis: the present and the future. Dig Liver Dis 2009; 41: 615-25.
2. Marchesini G, Bugianesi E, Forlani G, et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 2003; 37: 917-23. (Pubitemid 36397405)
3. Petta S, Craxì A,. Hepatocellular carcinoma and non-alcoholic fatty liver disease: from a clinical to a molecular association. Curr Pharm Des 2010; 16: 741-52.
4. Petta S, Tripodo C, Grimaudo S, et al. High liver RBP4 protein content is associated with histological features in patients with genotype 1 chronic hepatitis C and with nonalcoholic steatohepatitis. Dig Liver Dis 2011; 43: 404-10.
5. Argo CK, Northup PG, Al-Osaimi AM, et al. Systematic review of risk factors for fibrosis progression in non-alcoholic steatohepatitis. J Hepatol 2009; 51: 371-9.
6. Bugianesi E, Marchesini G, Gentilcore E, et al. Fibrosis in genotype 3 chronic hepatitis C and nonalcoholic fatty liver disease: role of insulin resistance and hepatic steatosis. Hepatology 2006; 44: 1648-55. (Pubitemid 44953669)
7. Shoelson SE, Herrero L, Naaz A,. Obesity, inflammation, and insulin resistance. Gastroenterology 2007; 132: 2169-80. (Pubitemid 46693756)
8. Despres JP, Lemieux I,. Abdominal obesity and metabolic syndrome. Nature 2006; 444: 881-7. (Pubitemid 46024995)
9. Chan DC, Watts GF, Ng TW, et al. Measurement of liver fat by magnetic resonance imaging: relationships with body fat distribution, insulin sensitivity and plasma lipids in healthy men. Diabetes Obes Metab 2006; 8: 698-702. (Pubitemid 44515568)
10. Thomas EL, Hamilton G, Patel N, et al. Hepatic triglyceride content and its relation to body adiposity: a magnetic resonance imaging and proton magnetic resonance spectroscopy study. Gut 2005; 54: 122-7. (Pubitemid 40007230)
11. van der Poorten D, Milner KL, Hui J, et al. Visceral fat: a key mediator of steatohepatitis in metabolic liver disease. Hepatology 2008; 48: 449-57.
12. Park BJ, Kim YJ, Kim DH, et al. Visceral adipose tissue area is an independent risk factor for hepatic steatosis. J Gastroenterol Hepatol 2008; 23: 900-7. (Pubitemid 351806572)
13. González-Reimers E, Castellano-Higuera A, Alemán-Valls R, et al. Relation between body fat and liver fat accumulation and cytokine pattern in non-alcoholic patients with chronic HCV infection. Ann Nutr Metab 2009; 55: 351-7.
14. Hourigan LF, Macdonald GA, Purdie D, et al. Fibrosis in chronic hepatitis C correlates significantly with body mass index and steatosis. Hepatology 1999; 29: 1215-9. (Pubitemid 29168757)
15. Adinolfi LE, Gambardella M, Andreana A, et al. Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. Hepatology 2001; 33: 1358-64. (Pubitemid 32496971)
16. Pouliot MC, Despres JP, Lemieux S, et al. Waist circumference and abdominal saggital diameter: best simple anthropometric indices of abdominal visceral adipose tissue accumulation and related cardiovascular risk in men and women. Am J Cardiol 1994; 73: 460-8. (Pubitemid 24096208)
17. Amato MC, Giordano C, Galia M, et al.; For the AlkaMeSy Study Group Visceral Adiposity Index (VAI): a reliable indicator of visceral fat function associated with cardiometabolic risk. Diabetes Care 2010; 33: 920-2.
18. Petta S, Amato M, Cabibi D, et al. Visceral adiposity index is associated with histological findings and high viral load in patients with chronic hepatitis C due to genotype 1. Hepatology 2010; 52: 1543-52.
19. American Diabetes Association. Report of the Expert Committee on the diagnosis and classification of diabetes mellitus. American Diabetes Association: Clinical Practice Recommendations 2000 Committee Report. Diabetes Care 2000; 23: S4-19.
20. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-97.
21. Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-9. (Pubitemid 15018832)
22. Ikeda Y, Suehiro T, Nakamura T, et al. Clinical significance of the insulin resistance index as assessed by homeostasis model assessment. Endocr J 2001; 48: 81-6. (Pubitemid 32230388)
23. Colloredo G, Guido M, Sonzogni A, et al. Impact of liver biopsy size on histological evaluation of chronic viral hepatitis: the smaller the sample, the milder the disease. J Hepatol 2003; 39: 239-44. (Pubitemid 36920560)
24. Kleiner DE, Brunt EM, Van Natta M, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005; 411: 313-21.
25. SAS Technical Report. SAS/STAT Software: Changes and Enhancement, Release 6.07. Cary, NC: SAS Institute, Inc., 1992.
26. Petta S, Cammà C, Cabibi D, et al. Hyperuricemia is associated with histological liver damage in patients with nonalcoholic fatty liver disease. Aliment Pharmacol Ther 2011; 34: 757-66.
27. Yilmaz Y,. Systematic review: caspase cleaved fragments of cytokeratin 18-the promises and challenges of a biomarker for chronic liver disease. Aliment Pharmacol Ther 2009; 30: 1103-9.
28. Dowman JK, Tomlinson JW, Newsome PN,. Systematic review: the diagnosis and staging of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. Aliment Pharmacol Ther 2011; 33: 525-40.
29. Petta S, Di Marco V, Cammà C, et al. Reliability of liver stiffness measurement in non-alcoholic fatty liver disease: the effect of Body Mass Index. Aliment Pharmacol Ther 2011; 33: 1350-60.
30. Wong VW, Wong GL, Choi PC, et al. Disease progression of non-alcoholic fatty liver disease: a prospective study with paired liver biopsies at 3 years. Gut 2010; 59: 969-74.
31. Tilg H, Hotamisligil GS,. Nonalcoholic fatty liver disease: cytokine-adipokine interplay and regulation of insulin resistance. Gastroenterology 2006; 131: 934-45. (Pubitemid 44307061)
32. Hui JM, Hodge A, Farrell GC, et al. Beyond insulin resistance in NASH: TNF-alpha or adiponectin? Hepatology 2004; 40: 46-54. (Pubitemid 38868922)
33. Musso G, Gambino R, Durazzo M, et al. Adipokines in NASH: postprandial lipid metabolism as a link between adiponectin and liver disease. Hepatology 2005; 42: 1175-83. (Pubitemid 43112685)
34. Kaser S, Moschen A, Cayon A, et al. Adiponectin and its receptors in non-alcoholic steatohepatitis. Gut 2005; 54: 117-21. (Pubitemid 40007229)
35. Crespo J, Cayón A, Fernández-Gil P, et al. Gene expression of tumor necrosis factor alpha and TNF-receptors, p55 and p75, in nonalcoholic steatohepatitis patients. Hepatology 2001; 34: 1158-63. (Pubitemid 33096588)
36. Poniachik J, Csendes A, Díaz JC, et al. Increased production of IL-1alpha and TNF-alpha in lipopolysaccharide-stimulated blood from obese patients with non-alcoholic fatty liver disease. Cytokine 2006; 33: 252-7.
37. Wieckowska A, Papouchado BG, Li Z, et al. Increased hepatic and circulating interleukin-6 levels in human nonalcoholic steatohepatitis. Am J Gastroenterol 2008; 103: 1372-9. (Pubitemid 351813900)